38results about How to "Prolonged bleeding time" patented technology

A non-contact controllable heater wound covering and method having a peripheral sealing ring covered by a layer to which is attached a heater and this assembly is attached to the skin with an adhesive so that the heater is held proximate the wound area in a non-contact position. The layer and peripheral sealing ring together define a treatment volume proximate the wound. The wound covering includes a programmable active heater control and the sealing ring may dispense water to control the humidity of the treatment volume. One form of active heat is an electrical resistive filament in variable geometric shapes providing versatility in application of heat to different types of wounds and wound area geometries. Another form of active heat is the transfer of a heated gas to the wound covering.

The present invention provides compounds and medicines effective for prophylaxis and therapy of various diseases by controlling or inhibiting cell-adhesion. Especially, the compounds of this invention perform platelet aggregation action without remarkable elongation of hemorrhagic period and can be used as a safe and long-acting antithrombotic drug as compared with known substances showing the same activity. Compounds of this invention are piperazinones of the formula

The present invention provides a synergistic phytochemical composition from Curcuma longa possessing analgesic and anti inflammatory activity used for management of chronic pain and treatment of osteoarthritis. The composition comprises Curcuma longa oil and Curcuma longa water extract. The relative amounts of these materials may be 0.5-5% by weight and 95-99.5% by weight respectively; and optionally pharmaceutically acceptable excipients.

The present invention also provides a process for preparing the composition.

The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including (a) a binding element capable of targeting an activated platelet and (b) a label. Applicant has shown that agents and probes directed to activated platelets are useful in the diagnosis and therapy of coagulation disorders.

The present invention relates to a pharmaceutical composition and method for treating and preventing musculoskeletal and connective tissue diseases of unknown etiology, such as different forms of arthritis and other rheumatic conditions, comprising a combination of therapeutic agents that improve the processes of blood circulation and angiogenesis in the affected tissues, as well as other supporting therapies. Among the components of herein proposed pharmaceutical composition, are: vitamin K, polyunsaturated fatty acids (blood thinner), and niacin (vasodilator and hypolipidemic agent).

The present invention relates to a female intrauterine drug delivery system, and more particularly to an intrauterine sustained control release drug delivery system adopting a biodegradation material, and a preparation method thereof. The present invention provides an intrauterine sustained control release drug delivery system adopting a biodegradation material, and a preparation method thereof, wherein the system has characteristics of short length, light weight, efficiency, and reversibility. The system comprises a sustained control release pipe, a drug core and a tail filament, wherein the sustained control release pipe is wrapped on the external of the drug core, the tail filament is positioned between the sustained control release pipe and the drug core or is accommodated in the middle of the drug core, the drug core is a rod prepared by blending progesterone or an available intrauterine sustained control release drug and a biodegradable polymer, and the sustained control release pipe is made of a biodegradable polymer. The system of the present invention has characteristics of no stent, no copper ion, safety, practicality, and simple placement technology.

A microscopic protein device and the method of manufacture and the use of such a device for hemostasis. The device, made with biologic material such as serum albumin from a human or animal source, is less than five micron in any one dimension and typically less than one micron in diameter. It does not have any other biological or drug molecules attached to it in vitro. However, the device has properties that allow it to capture, concentrate, carry or bind biomodifying molecules, such as coagulation factor(s), or potentially other drugs, after exposure to plasma in vitro; and possibly in vivo as well. After infusion of said device intravenously inside the body, hemostatic effects can be demonstrated.

The present invention relates to a female intrauterine drug delivery system, and more particularly to a novel intrauterine sustained control release drug delivery system and a preparation method thereof. The present invention provides a novel intrauterine sustained control release drug delivery system and a preparation method thereof, wherein the system has characteristics of short length, light weight, efficiency, and reversibility. The system comprises a sustained control release pipe, a drug core and a tail filament, wherein the sustained control release pipe is wrapped on the external of the drug core, the tail filament is positioned between the sustained control release pipe and the drug core or is accomodated in the middle of the drug core, the drug core is a rod prepared by blending progesterone or an available intrauterine sustained control release drug and a biodegradable polymer, and the sustained control release pipe is made of a silicon rubber. The system of the present invention has characteristics of no stent, no copper ion, safety, practicality, and simple placement technology.

The present invention relates to chimeras of human tissue factor inhibitor domain 1 with natural and non-natural Kunitz domains, and their preparation and use.

The invention relates to a hexadecapeptide compound and a preparation method and application thereof. The polypeptide sequence of the hexadecapeptide compound is one or more of RTGACFCVIYNGILYP, or the sequence with the 1-site amino acid R replaced by K, the sequence with the 2-site amino acid T replaced by S, the sequence with the 8-site amino acid V replaced by I or L, the sequence with the 9-site amino acid I replaced by V or L, the sequence with the 11-site amino acid N replaced by Q, the sequence with the 13-site amino acid I replaced by V or L, and the sequence with the 14-site amino acid L replaced by V or I. The hexadecapeptide compound has the functions of prolonging bleeding time, remarkably inhibiting platelet aggregation, and preventing thrombosis, has low toxicity, and has broad application prospects in preparing anti-platelet aggregation or antithrombotic drugs, drug components or prodrugs. The preparation method has high yield and simple process.

The invention belongs to the field of medical immunity, and provides a sulfated Lachnum extracellular polysaccharide and application thereof in anticoagulant drugs. The sulfated Lachnum extracellular polysaccharide is prepared by carrying out sulfur trioxide-pyridine composite sulfation modification on Lachnum polysaccharide LEP-1 which is secreted and extracted from Lachnum YM281. The pharmacological experiment proves that the sulfated Lachnum extracellular polysaccharide has prolonging actions on mouse bleeding time (BT) and mouse coagulation time (CT) under the conditions of both low dose (30 mg/kg) and high dose (90 mg/kg), which indicates that the sulfated Lachnum extracellular polysaccharide has an anticoagulation action, thereby providing a new way for anticoagulation research.

The present invention provides a process of producing highly purified proteases. The invention further provides the use of such purified proteases in treating cardiovascular disorders, including hypertension, stroke and thrombosis.